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POPULAR SCIENCE  
Not all diseases get cured completely. Hematological malignancies are cancers derived from 
blood/bone marrow or lymphatic tissues and are divided into many subtypes. How these 
malignancies are formed is incompletely understood. For many patients diagnosed with these 
cancers, the current treatment needs great improvement to gain better clinical efficacy. Thus, it 
is essential to explore the mechanisms underlying these hematological malignancies, thereby 
developing new treatment strategies. 
Hodgkin lymphoma (HL) is a malignant disease derived from B cells. HL development is 
thought to be related to many factors, including age, gender difference, familial and genetic 
risk, environmental factors, etc. We described monozygotic triplets, carrying the same DNA 
profiles. Two of them developed HL, while the other remained HL free. We found that these 
two HL triplets had certain similarity in some markers located on top of the DNA sequence of 
their hematopoietic cells. The finding might be helpful for better understandings of the 
development of HL. 
Myeloproliferative neoplasms (MPNs) are a group of myeloid disease derived from the bone 
marrow. The treatment of MPNs is mostly not curative.  Janus kinase 2 (commonly called 
JAK2) is an enzyme that is involved in some cell signaling pathways and the development of 
cancers. A JAK2 inhibitor LY2784544 could affect the activity of an important signal pathway 
in normal human life as well as the formation of cancers. In a large number of MPN patients, 
there is a gene mutation occurring in the JAK2 gene called JAK2V617F. Increased JAK2 activity 
leads to the accumulation of progenitor and mature blood cells. There is an enzyme in our body 
called telomerase which is important in cell life-span, and cancer development. We found that 
the drug GRN163L targeting telomerase together with a JAK2 inhibitor might be potentially 
used as a novel treatment strategy for MPNs. 
The enzyme 5-LOX is generally thought to be related to the metabolism of lipids. It has been 
reported to be related to some B cell-related diseases. We found that this enzyme is correlated 
with the migration and adherence of mantle cell lymphoma (MCL). Inhibiting the migration 
and adhesion of MCL cells to secondary lymphatic tissues can block the protection malignant 
cells get by crosstalk with the microenvironment. Compounds that inhibit 5-LOX may be 




Hematological  malignancies  originate  from  hematopoietic  cells  in  the  bone  marrow  or  the 
lymphatic  system.  In  this  thesis,  I  study  the  molecular  pathogenesis  of  Hodgkin  lymphoma 
(HL), mantle cell lymphoma (MCL), and myeloproliferative neoplasms (MPNs), and explore 
the underlying therapeutic implication in these diseases.
In paper  I, we  profiled  the  DNA  methylation  signature  in  blood  cells  from  monozygotic 
triplets, two of which had developed HL. Isolated CD34+ hematopoietic cells, marginal zone- 
like and naïve B-cells, and switched memory B-cells were compared for the difference in global 
DNA methylation between the triplets with the one without HL. Shared differences were 
found in naïve B-cells and marginal zone-like B-cells. One region in chromosome 18 was found 
to be hyper-methylated in the naïve B-cells, while 21 genomic regions on 10 chromosomes 
were  hyper-methylated  in  marginal-zone  like  B-cells  derived  from  the  HL  triplets.  These 
findings may indicate a role of aberrant DNA methylation in HL pathogenesis.
In paper II, we probed new therapeutic strategies for MPNs. The activating JAK2V617 mutation 
drives  MPN  development.  Treatment  with  JAK2  inhibitors  frequently  leads  to  therapeutic 
failure,  and  the  underlying  mechanism  is  elusive.  We  observed  that  the  JAK2  inhibitor 
LY2784544 caused the transient decrease in viability and proliferation of the JAK2V617-bearing 
cell line HEL, but induced the accumulation of leukemic stem cell (CD34+) cells. The stem 
cell factor KLF4 was highly expressed upon LY2784544 treatment, whereas silencing of KLF4 
attenuated the accumulation of LY2784544-induced accumulation of CD34+ cells. A similar 
effect  was  also  identified  in  cells  treated  with  the  telomerase  inhibitor  GRN163L  after 
LY2784544  incubation.  Thus,  targeting  KLF4  combined  with  a  JAK2  inhibitor,  or 
combination of telomerase inhibitor and JAK2 inhibitors may potentially be used as a novel 
treatment strategy for MPN patients.
In paper III, we investigated the role of 5-lipoxygenase (5-LOX) in MCL and evaluated the 
effect of inhibition of 5-LOX as a therapeutic strategy. Human B lymphocytes express 5-LOX 
and  5-LOX-activating  protein  (FLAP),  and  can  convert  arachidonic  acid  to  leukotriene  B4. 
MCL cells express large amounts of 5-LOX, but the function and mechanism of activation of 
5-LOX in B lymphocytes are unclear. We demonstrated that the intrinsic 5-LOX pathway in 
the MCL cell line JeKo-1 has an essential role in the migration and adhesion of these cells. 5- 
LOX and  FLAP  inhibitors  reduced  the  migration  induced  by  the  chemoattractant  CXCL12. 
The knockout of the 5-LOX gene also decreased the migration of JeKo-1 cells. Furthermore, 
the above inhibitors inhibited adherence of JeKo-1 cells to stromal cells. The inhibitors were 
as  potent  as  the  Bruton  tyrosine  kinase  inhibitor  ibrutinib,  a  therapeutic  agent  in  MCL 
treatment, to inhibit migration and adherence of MCL cells. Our results suggest that inhibition 
of  the  5-LOX  pathway  may  be  an  important  strategy  in  the  treatment  of  certain  B-cell 
malignancies.
Taken together, the findings presented in this thesis contribute to better understandings of the 
molecular pathogenesis of HL, MCL, and MPNs, and are implicated in the rational development 
of novel therapeutic strategies for these malignancies.
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1    INTRODUCTION 
Hematological malignancies originate from hematopoietic cells in the bone marrow or the 
lymphatic system. Although there has been a lot of improvement in the clarification of these 
diseases, current treatments are not always satisfying. It is therefore of importance to further 
gain insights into the pathogenesis of these malignancies for rational development of novel 
treatments. We performed this study on the molecular pathogenesis of Hodgkin lymphoma 
(HL), mantle cell lymphoma (MCL), and myeloproliferative neoplasms (MPNs), exploring the 
underlying therapeutic implication in these diseases. 
Our group previously reported a male monozygotic triplet case, two of these triplets were 
diagnosed with HL, while the other one is free of HL. We found that there is a deletion in the 
first intron of the megakaryoblastic leukemia 1 (MKL1) gene on chromosome 22 in all of these 
three triplets (1). To further explore whether epigenetic factors affect the development of HL, 
we examined the Deoxyribonucleic acid (DNA) methylation profiles of four cell 
subpopulations derived from peripheral blood mononuclear cells (PBMCs) of the triplets, and 
our findings could be of importance in the understanding of HL pathogenesis.  
A poor prognosis of patients with MPNs is sometimes related to resistance-treatment with JAK 
2 inhibitors. JAK2V617F is a gain-of-function mutation that is present in the vast majority of 
MPNs, and JAK2 inhibitors have moderate efficacy in the treatment of MPNs. Telomerase 
activation is very common in many types of cancers (2), and a telomerase inhibitor, GRN163L, 
was reported to show promising effects in the treatment of MPNs and some other hematological 
diseases (3-5).  Here we report our findings in a human erythroleukemia cell line HEL which 
carries the JAK2V617F mutation, aiming to find out whether the telomerase inhibitor and JAK2 
inhibition shows synergistic effect in the treatment of MPNs. 
MCL is derived from B lymphocytes, these malignant cells have a relative high-expression of 
5-lipoxygenase (5-LOX) (6-8). 5-LOX belongs to the lipoxygenase family and the enzyme 
converts fatty acid to leukotrienes (LTs) which are important mediators of allergic and immune 
reactions. Here we have studied the role of 5-LOX pathway in the migration and adhesion in 






2    LITERATURE REVIEW 
2.1    HODGKIN LYMPHOMA 
Hodgkin lymphoma (HL) is a type of lymphoma, formerly called Hodgkin´s disease which 
originates from the lymphatic system. It was named after Thomas Hodgkin who was the first 
pathologist describing this disease (9). HL tumors have a unique feature in that the tumor 
contains only 1-2% malignant cells (Hodgkin and Reed/Sternberg cells, HRS) which are 
believed to originate from a post germinal centre B-cell. The rest of the tumor 
microenvironment mainly harbours inflammatory cells of the immune system, stromal cells, 
macrophages, eosinophils, mast cells and plasma cells (10).  
2.1.1    Epidemiology 
In 2018, about 80,000 new cases were estimated to contribute to the newly diagnosed cancer 
patients in the world and 26,000 patients died from HL (11). The estimated age-standardized 
incidence was approximately 2.4 cases per 100,000 persons per year, and the number of deaths 
was about 0.33 person per 100,000 persons per year in Europe.  
HL is divided into two major groups according to the appearance of tumor cells and the 
composition of inflammatory background: classical Hodgkin lymphoma and Nodular 
lymphocyte predominant HL. Classical Hodgkin lymphoma (cHL) can then be subdivided into 
four subgroups, Nodular sclerosis classical HL (NSHL), Mixed cellularity classical HL 
(MCHL), Lymphocyte rich classical HL (LRHL), Lymphocyte depleted classical HL (LDHL). 
Nodular sclerosis subtype is the most common cHL which accounts for about 70%-80% of all 
HL cases, mixed cellularity cHL accounts for about 15% (12), and the other two types of HL 
are rare. HL has a bimodal age-incidence pattern, it has a high incidence peak for children and 
young adults, the second incidence peak appears at an older age. 
2.1.2    HL and families 
Numerous studies have shown that genetic factors are involved in the HL pathogenesis. Goldin 
et al (13) collected and analyzed the data from first-degree relatives of patients with HL and 
the first-degree relatives of control groups from Sweden and Denmark. The results suggested 
that, although the relative risks were not the same, the risk of relatives of HL was higher 
compared with control groups in both Sweden and Denmark, and the incidence risk among 
siblings was higher among the first-degree relatives. The difference was more obvious in males 
than females (14). Besides, the risk was almost double in same-sex siblings than opposite-sex 





the patients were found to have greater incidence risk; and 10 pairs of the monozygotic twins 
showed concordance, while no correlation was shown in dizygotic twins. A Swedish national 
cohort study in which 3.57 million individuals were involved showed that the children or young 
adults who had HL familial history in a sibling or parent had about 8.83 and 7.19 higher risk to 
develop HL, respectively (16). 
2.1.3    HL and epigenetics 
Epigenetics explains how the phenotype can be changed without change of DNA sequences. 
The cellular and phenotype change may be caused by external and environmental factors, as 
well as the alteration happening in normal development. DNA methylation and histone 
modification are the two major mechanisms that cause epigenetic alterations. The methylation 
of CpG sites in the promoter region mediates the silence of gene transcription.  
On the phenotypic level there can be quite pronounced differences between monozygotic twins, 
and many studies have shown that epigenetic differences may contribute to these differences 
(17). Fraga et al (18) found that monozygotic twins have different epigenetic signatures, which 
provides a new insight for scientists in studying the role of epigenetic factors in phenotype 
differences. Wang´s group (19) compared the DNA methylation differences in twins, they 
found a higher DNA methylation level at the TCF3 locus in HL survivors than their unaffected 
twins, however, no difference was found in the healthy-twin groups.  
Hyper-methylation was mostly found in the promoter region of tumor suppressor genes. Ying 
et al (20) found that aberrant methylation of tumor suppressor gene DLC1 promoter was 
detected in 4/6 HL cell lines, and 44% HL patients. The hyper-methylation of DLC1 was also 
viewed as a biomarker of early diagnosis and prognosis. 3p22 cluster genes were demonstrated 
by numerous studies to have tumor suppressor function in a lot of malignancies; and a member 
of 3p22 gene, DLEC1, was also found to be silenced by methylation at CpG island of the 
promoter (21). TET1 belongs to the TET family of DNA hydroxylases, and TET proteins are 
active CpG demethylases and they convert 5-methylcytosine to 5-hydroxymethylcytosine. It 
was reported to be frequently methylated in HL patient samples, which also supported the 
tumor suppressor function of TET1 (22). Similar phenomena were also observed in some other 
tumor suppressor genes such as RASSF1A (23), PCDH10 (24), PRDX2 (25).  
The silence of B-cell specific genes such as CD79B, BOB1, SYK, PU.1, CD19, CD20 was also 
found in cHL, and DNA methylation contributes to the silence of these genes (26). Besides, 
histone acetylation and DNA demethylation of B cells can induce extinction of B cell-specific 
genes, and result in up-regulation of some HL specific genes. Interestingly, one feature of HRS 
4 
 
cell is the loss of B cell phenotype, suggesting a role of epigenetic alterations in the formation 
of HL. 
Hyper-methylation of several tumor-associated genes such as P16, DAPK, GSTP1, CDH1 had 
been found in both EBV positive and negative HL (27), these genes are thought to be involved 
in cell cycle regulation, apoptosis, and DNA repair, being-important in cancer development. 
Micro ribonucleic acids (MiRNAs) can function as tumor suppressor genes or oncogenes, 
miR34a and miR203 are tumor suppressor genes in some cancers, and they were also hyper-
methylated in HL cell lines and tissue samples from HL patients (28). Dhiab et al (29) also 
found that methylation of tumor suppressor microRNA miR9, especially miR9-2, is frequently 
observed in HL patient samples, irrespective of EBV infection.  
2.2    TELOMERE AND TELOMERASE 
Telomere is the nucleoprotein structure formed at the end of chromosomes. Telomere and its 
binding proteins (POT1, RAP1, TRF1, TRF2, RAP1, TPP1) work together to keep the genome 
stability (30). It is commonly believed to be related to aging in humans, and the shortening of 
telomere is observed in human tissues as people age (31). 
2.2.1    Telomerase 
Telomerase is a ribonucleoprotein enzyme that belongs to the reverse transcriptase family. 
Telomerase reverse transcriptase (TERT) and internal telomerase RNA template (TERC) 
constitute the core of telomerase to lengthen telomere (32). In most human cancers, telomerase 
is reactivated by induction of TERT expression. The telomerase activity is detected in 
hematopoietic cells, germ cells and stem cells. Besides, telomerase activity and the 
maintenance of telomere are thought to be highly related to the progression of a large number 
of human malignancies (33). It regulates the progression of cancers mainly through mediating 
the unlimited division of tumor cells (34). TERC is a non-coding RNA as the template for 
telomeric DNA synthesis.  
Telomerase has long been thought of as a therapeutic target for cancers. Of all the telomerase 
inhibitors, GRN163L (also named as imetelstat) was thought to be one of the most effective 
inhibitors.  It provides a competitive inhibition effect with telomerase through binding to the 








Figure 1. GRN163L inhibits telomerase activity through the binding of human telomerase RNA 
template.
2.2.2    Telomere maintenance mechanism and regulation of telomerase reverse
transcriptase (TERT) expression
The telomere maintenance is regulated by TERT reactivation through different mechanisms, 
including TERT/TERC gene amplification, TERT promoter mutations, epigenetic alterations, 
transcription  factor  regulation,  alternative  splicing,  and  polymorphic  variants  (36).  The 
TERT/TERC  gene  copy  number  changes  in  chromosomes  result  in  the  alteration  of  gene 
expression.  TERT  promoter  mutation  is  common  in  the  non-coding  region,  and  the  most 
common TERT promoter mutations occur at -124bp and -146bp from the transcription starting 
site. The mutation is usually C>T transition, and the two hotspot mutations above are so-called 
C228T and C250T, respectively (37, 38).
The  epigenetic  regulation  is  very  common  in  cancers  (39),  TERT  promoter  methylation  is 
another  kind  of  regulatory  mechanism  in  the  TERT  expression,  as  well  as  the  telomerase 
activity  (40).  The  promoter  of  TERT  has  many  binding  sites  of  transcriptional  factors  that 
activate or repress the gene expression, and many important signal pathways were reported to 
be related to the regulation of TERT expression as well as telomerase activity, for example, 
RAS/RAF/MEK pathway, PI3K/AKT pathway, IKK/NF-κB pathway, JAK-STAT pathway, 
etc  (41).  Single  nucleotide  polymorphisms  (SNPs)  at  the  TERT  locus  have  been  related  to 
prognosis  of  many  cancers  (42-44).  The  posttranscriptional  regulation  of  TERT  was  also 
detected by some research groups, for example, the TERT gene pre-mRNA alternative splicing 
(36), however, the exact role of this splicing wasn´t completely clarified yet.
2.3    MYELOPROLIFERATIVE NEOPLASMS (MPNS)
MPNs  are  derived  from  hematopoietic  cells  in  the  bone  marrow,  and  they  include  three 
subtypes:  polycythemia  vera  (PV),  essential  thrombocythemia  (ET),  primary  myelofibrosis 
(PMF). Patients  with  advanced  disease  have  symptoms  including  fatigue,  weight  loss,
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weakness,  enlarged  spleen.  The  identification  of  the  Janus  kinase  2  (JAK2)  mutations  was 
found to be related to MPNs in 2005. JAK2V617F mutation is the most important mutation in 
MPNs and is commonly found in ET, PV, and PMF.
2.3.1    Epidemiology of MPNs
MPNs  are  believed  to  be  rare  hematological  diseases,  however,  the  incidence  is  growing 
recently. The incidence rate of MPNs roughly varied from 1.15 to 4.99 persons per 100,000 
persons per year (45-47). In Sweden, the annual incidence of all MPNs was about 4.45 persons 
per 100,000 persons from 2000 to 2014 (48).
2.3.2    Janus Kinase 2 (JAK2) inhibitors in the treatment of MPNs
So far, there have been no curable treatment strategies for MPNs, with most treatments focused 
on the relief of symptoms and control of the proliferation of blood cells. For a small number of 
patients, hematopoietic stem cell transplantation might be used as a very effective treatment 
strategy.  JAK2  is  a  kind  of  non-receptor  tyrosine  kinase  characterized  by  the  lack  of  Src 
homology binding domains but with seven Janus homology domains (JH1-JH7). It is essential 
in  many  biological  processes  including  cell  growth,  cancer  development,  differentiation, 
immune response, etc. It affects many signaling pathways through binding of type I or type II 
receptors  in  cells.  JAK2  is  involved  in  the  biological  actions  through  activation  of  MAPK, 
PI3K as well as AKT pathways (49).
Mutations of JAK2 have been identified in PV, ET, and PMF (50). The most common JAK2 
mutation harbours the homozygous G to T transversion and the phenylalanine was substituted 
for valine at 617 of JAK2 (JAK2V617F). The percentage of JAK2V617F mutation varies in patients 
with ET, PV and PMF. The JAK2 mutation was also thought to contribute to the diagnosis of 
PV (51). Almost all PV cases were found to carry JAK2V617F mutation, while only 50% of ET 
and PMF patients were reported to have JAK2V617F mutation (52, 53).
Some JAK2 inhibitors are now in clinical use for the treatment of MPNs. Thus, several drugs 
were approved by Food and Drug Administration (FDA) or European Medicines Agency for 
the treatment of MPNs. Ruxolitinib has been approved to treat MF (54). Fedratinib is another 
JAK2 inhibitor that was approved by FDA for the treatment of intermiediate-2 or higher risk 
MF patients (55). However, there are some limitations of JAK2 inhibitors in the treatment of 
MPNs. Because JAK2 inhibitors could not bind specifically to the mutant protein during the 
treatment, the off-target phenomenon is very common in drug treatment. For example, JAK1 
and FLT3 might be affected during the JAK2 inhibition (56). An interesting phenomenon is 





a more general effect of JAK2 inhibitors for the treatment of MPNs. However, JAK2 inhibition 
is not so far a curative therapy.  
The combination of JAK2 inhibitors and telomerase inhibitors has been reported to have an 
effect on the treatment of some MPN patients. According to a clinical trial, for 33 of the 
intermediate-2 or high-risk MF patients who had GRN163L treatment, 48% of them received 
prior JAK2 inhibitor treatment. Twenty-one percent of them showed a complete or partial 
remission (3), supporting a promising future of GRN 163L in the treatment of MPNs. 
2.4    LIPOXYGENASE AND ITS METABOLITES 
Lipoxygenase (LOX) is a family of enzyme which converts polyunsaturated fatty acid such as 
arachidonic acid and linoleic acid into mediators playing important roles in asthma, allergic 
reactions and in the immune system. These mediators act as local hormones in the body. In 
humans, six LOX genes were identified, including ALOX-5, ALOX-12, ALOX-15, ALOX15B, 
ALOX12B, ALOXE3.  
2.4.1    5-lipoxygenase (5-LOX) and 5-lipoxygenase-activating protein (FLAP) 
The 5-LOX pathway plays an important pathophysiological role in certain diseases, and 5-
LOX is the key enzyme in the formation of LTs. Arachidonic acid can be converted to 5-
hydroperoxide eicosatetraenoic acid (5-HPETE) and then further converted to LTA4 under the 
catalysis of 5-LOX, or transformed to 5-hydroxyeicosatetraenoic acid (5-HETE) by GSH 
peroxidases (58). In different cell types, LTA4 is converted to either LTB4 by LTA4 hydrolase, 
or to LTC4 by LTC4 synthase, respectively (Figure 2). LTC4 can be subsequently metabolized 
into LTD4, and LTE4. 
5-LOX is found to be highly expressed in many types of leukocytes, such as monocytes, 
dendritic cells (DC), mast cells and B lymphocytes. The metabolites of the 5-LOX pathway 
have been implicated in many diseases, such as asthma, allergic disorders, atherosclerosis, 
Alzheimer´s disease, and some cancers (59-61). In cancer cells, some studies indicate that 5-
LOX regulates cell proliferation and cell growth (62). CYSLTR1 antagonists are efficient drugs 
for the treatment of asthma and some allergic diseases. Zileuton is a potent selectively inhibitor 
of 5-LOX, and it is used in patients with severe asthma in USA. Some studies indicate that it 
might also be useful in the treatment of chronic myeloid leukemia (63). 
FLAP is a protein that contributes to the cellular production of LTs. It is important in the 
conversion of endogenous arachidonic acid by 5-LOX and function as the anchor of 5-LOX 
protein in the membrane. There are some FLAP inhibitors used in clinic trials and scientific 
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research such as MK886 and GSK2190915. MK886 was first identified by Merck-Frosst in the 
1980s, and found to selectively affect LT production (64). GSK2190915 is another potent 
FALP inhibitor, being tested in the treatment of asthma (65). Some FLAP inhibitors have been 
in clinical trials for the treatment of asthma and other inflammatory disorders but no one has 
yet come to the market (66). 
 
Figure 2. Schematic diagram of the 5-LOX pathway. 
2.4.2    Leukotrienes 
Leukotrienes (LTs) are produced by leukocytes and belong to the eicosanoid family, and are 
involved in the regulation of the immune system (Figure 3) (67). Exogenous addition of LTB4, 
induces the production of IL-2 and, IL-4 in human T cells, and also promotes the proliferation 
of CD4 T cells. In B-chronic lymphocytic leukemia cells, LTB4 was found to play a pivotal 
role in CD40-dependent activation of the cells (68). LTB4 functions as a chemoattractant and 
induces the chemotaxis in macrophages, neutrophils and DC (69). The production of LTs 
causes inflammation mainly mediated by cysteinyl LTs and LTB4. Cysteinyl-containing LTs 
include LTC4, LTD4 and, LTE4.  
LTB4 was first reported to be one of the most potent chemotactic agents in 1980 (70), and it 
was found to promote the migration of leukocytes towards inflammatory tissues (71), increase 
the phagocytosis (72), and promote the antimicrobial defense (73). Our research group found 
that arachidonic acid could be converted to LTB4 in B lymphocytes (74). The mechanism of 
activation of LT synthesis in B-cells is unclear. It has been known that B lymphocytes can 
produce LTB4 in the homogenate and after changing cellular redox status (75), but the 
formation of LTB4 has never been reported in B lymphocytes under physiological conditions. 





in asthma, and drugs which block Cysteinyl Leukotriene receptor 1 (CYSLTR1) are very 
commonly used in the treatment of asthma (76). LTB4 is produced by leukocytes such as 
neutrophils, B lymphocytes, monocytes, macrophages, eosinophils and mast cells.  
 
Figure 3. The effects of LTB4 in the immune system in the human body. 
2.5    MANTLE CELL LYMPHOMA (MCL) 
2.5.1    Epidemiology 
MCL belongs to non-Hodgkin lymphoma (NHL), it represents about 6% of all NHL patients, 
and the incidence of MCL in western countries is about 0.5 person per 100,000 persons per 
year (77, 78). In western countries, the incidence is found to be higher than in Asian countries 
(79, 80). However, the incidence of MCL is rising during recent years. Although MCL does 
occur in young adults, most patients are diagnosed at the age of 60 or 70 (81). About 3/4 of all 
the MCL patients are male.  
2.5.2    Etiology 
The MCL risk factors have not been fully clarified yet. However, some studies indicate that the 
incidence of MCL is believed to be correlated with familial factors, Borrelia infection, 
polymorphisms in IL-10. In addition, some researchers also found a relationship between 
autoimmune disease and the incidence and the prognosis of MCL patients. MicroRNAs are 
also reported to play a role in the etiology of MCL (82).  
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2.5.3    Pathogenesis 
MCL is thought to be caused by the combination of several somatic mutations in cells. The 
aberrant cell cycles, DNA damage, BCR cell signaling, the lymphoid tissue microenvironment 
with the cancer tissues contribute to the MCL pathogenesis. The cyclin D1 overexpression, 
SOX-11 overexpression, TP53 mutation,  NOTCH1/2 mutations (83) are thought to be related 
to the pathogenesis of MCL, too. 
2.5.4    Treatment of MCL 
MCL is a disease with a dismal outcome. The treatment of MCL now still needs great 
improvement since almost all patients will finally relapse. Nowadays there are four main kinds 
of treatment strategies, including chemotherapy, immune therapy, radiotherapy, and some 
novel agents in clinical trials. Chemotherapy is the most commonly used treatment in MCL. 
However, the treatment with chemotherapy could not be repeated because of some severe side 
effects such as hematologic suppression. The combination of CHOP and rituximab monoclonal 
antibody is common in MCL treatment, and patients benefit from the prolonged drug efficacy. 
Rituximab in combination with thalidomide was also reported to show some effect in the MCL 
treatment (84). Zanubrutinib and Brexucabtagene autoleucel were recently approved by FDA 
for the treatment of patients who are refractory to chemotherapy (85, 86). 
Ibrutinib is a Bruton protein-tyrosine kinase (BTK) inhibitor binding to BTK and inhibits BTK 
activity which is essential for B cells, thereby causing the defect of B cell receptor signaling 
pathway. Ibrutinib could also lead to the interference of CD40 signaling related to the migration 
of B cells towards the lymph node (87, 88). Ibrutinib is now commonly used in the treatment 
of patients diagnosed with chronic lymphocytic leukemia, MCL and Waldenstrom´s 
macroglobulinemia (89). Ibrutinib was approved by FDA in the USA for the treatment of MCL 











3    STUDY AIMS 
Overall, we aimed at exploring the pathogenesis of common hematological malignancies (HL, 
MPNs, MCL) for the rational development of new therapeutic strategies. Specially in each 
paper, the study aims are: 
1. To explore the role of DNA methylation in the pathogenesis of HL, by analyzing 
monozygotic triplets. 
2. To determine how JAK2 inhibitor LY2784544 affects the JAK2V617F bearing cell line 
HEL, and explore whether telomerase inhibitor GRN163L could help to gain a better 
therapeutic effect in MPNs. 

























4    MATERIALS AND METHODS 
4.1    PATIENT SAMPLES (PAPER I) 
The triplet blood samples were collected at the same time at the Department of Hematology, 
Karolinska Hospital. These studies were approved by the ethics committee of Karolinska 
Institutet. All the experiments were performed according to the guidelines of Karolinska 
Institutet. Informed consent was obtained from all participants before these studies.  
4.2    CELL LINES AND CELL CULTURE (PAPERS II, III) 
Human erythroleukemia cell line HEL was used in paper II, and MCL cell line JeKo-1, T cell 
line Jurkat, Molt-3 cell lines, and human stromal cell line HS-5 were used in paper III. All cells 
were cultured at 37℃. RPMI or DMEM supplemented with 10% FBS, 1U/ml PenStrep and 1% 
L-glutamine was used as the culture medium.  
4.3    WESTERN BLOT (WB) ANALYSIS (PAPERS II, III) 
Cell pellets were extracted with RIPA lysis buffer (Thermo Scientific, USA). Protein 
concentration was detected by Bicinchoninic acid assay (BCA) kit (BIO-RAD, USA), and 
same amount of protein was loaded into wells of mini-protein TGX gels (BIO-RAD, USA) 
followed by protein transfer to polyvinylidene difluoride (PVDF) membranes (BIO-RAD, 
USA). The membrane was blocked with 5% milk for one hour at room temperature, and the 
membrane was incubated with 5-LOX or KLF4 antibodies overnight at 4℃. Goat anti-rabbit 
or mouse secondary antibodies were used after primary antibody incubation. Membrane was 
developed after activation with ECL substrate (BIO-RAD, USA).  
4.4    RNA EXTRACTION AND Q-PCR ANALYSIS (PAPER II) 
Total RNA was extracted using Trizol (Life technologies) according to the manufacture´s 
instruction. RNA quantitation was detected by Thermo Scientific™ NanoDrop™ 2000/2000c 
Spectrophotometers. Quantitative real-time polymerase chain reaction (q-PCR) was carried out 
with SYBR (Appliedbiosystems, UK) and specific primers. Primers used for q-PCR are listed 
below in table 1.   







4.5    CELL TREATMENT (PAPERS II, III) 
In paper II, HEL cells were treated with JAK2 inhibitor LY2784544 (working concentration is 
0.5 μM) and the specific telomerase inhibitor GRN 163L (working concentration is 20 μM). In 
Paper III, FLAP inhibitor GSK2190915, MK886, 5-LOX inhibitor zileuton, and BTK inhibitor 
Ibrutinib were used in the treatment of cell line JeKo-1, Jurkat, Molt-3. GSK2190915, MK886, 
Ibrutinib, and zileuton were used starting from the concentration of 0.1 μM to 1 μM.  The 
structure of all compounds is listed below in Figure 4. 
 
Figure 4. Chemical structures of compounds. 
Forward Reverse
β-2M 5'-GAATTGCTATGTGTCTGGGT-3' 5'-CATCTTCAAACCTCCATGATG-3'
KLF4 5'-TCAGCGTCAGCCTCCTCTT-3'   5'-TTGATGTCCGCCAGGTTGAA-3'          
TERT 5'-CGGAAGAGTGTCTGGAGCAA-3'                      5'-GGATGAAGCGGAGTCTGGA-3'
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4.6    CD34+ CELL AND B-CELL SUBPOPULATION ISOLATION (PAPERS I, II) 
CD34+ subpopulations and CD34+ HEL cells were isolated with CD34+ isolation kit. B-cells 
were sorted from the PBMCs using CD20+ positive selection isolation kit. CD20+ cells were 
labeled with CD19 (APC-Cy7), IgD (FITC) and CD27 (PE) antibodies (BD). Naïve (IgD+ 
CD27-), marginal zone-like (IgD+ CD27+) and switched memory (IgD- CD27+) B-cells were 
sorted using FACS Aria (BD). 
4.7    DNA METHYLATION ANALYSIS (PAPER I) 
Genomic DNA was isolated from CD34+ cells, Marginal zone-like B-cells, Naïve B-cells, and 
switched memory B-cells with the DNeasy Blood & Tissue Kit (Qiagen). Bisulfite conversion 
was performed using the EZ DNA MethylationTM Kit D5004 (Zymo Research), and the 
bisulfite converted DNA was eluted in 15μl according to the manufacturer´s protocol. DNA 
methylation of genomic DNA was performed with Illumina EPIC array.  
4.8    MIGRATION ANALYSIS (PAPER III) 
JeKo-1 cell line, Jurkat cell line and Molt-3 cell line were seeded in 12-well plates. After 
inhibitor incubation in serum-free medium (SFM) for four hours, cells were collected and 
transferred to the upper chamber of 6.5 mm transwell plates with 8 μm pore (Corning 
Incorporated, USA) for two hours. CXCL12 was used in the lower chamber as the chemo-
attractant, and the cells in the lower chamber were collected and counted with Burker chamber.  
4.9    COLONY FORMATION ANALYSIS (PAPER II) 
HEL cells pretreated with JAK2 inhibitor LY2784544 for 4/8 weeks and telomerase inhibitor 
GRN163L for 4/8 weeks were used for the colony formation analysis. Five-hundred cells/well 
were seeded in a 6 well plate cultured with Methocult H4100 and RPMI 1640. Methocult 
H4100 was used for the formation of growth of leukemic progenitor cells. After 10 days of cell 
culture, cell colonies that contain 25-50 cells or more than 50 cells were counted. 
4.10    FLOW CYTOMETRY (PAPERS I, II, III) 
In paper I, the isolation of sub-B populations was performed with flow cytometry. In paper II, 
Annexin V-FITC/7-AAD kit (Beckman coulter) was used for the detection of cell apoptosis. 





4.11    TELOMERASE ACTIVITY ASSAY (PAPER II) 
The telomerase activity was detected by telomeric repeat amplification protocol (TRAP) 
ELISA KIT (Roche, Switzerland). Telomerase elongated the 3´ end of a biotin-labeled 
synthetic primer with 1μg lysate of HEL, the product was amplified with initial PCR under the 
condition of 25 cycles. The amplified products were denatured and hybridized to digoxigenin 
(DIG)-conjugated detection probes specific to the telomeric sequence. The products were then 
affixed to a streptavidin-coated microplate by the biotin. Amplified products stuck to the 
microplate were bound to antibodies against DIG, conjugated with horseradish peroxidase and 
the peroxidase substrate. The level of telomerase activity was expressed as absorbance 
determined with an ELISA reader.  
4.12    TELOMERE LENGTH ANALYSIS (PAPER II) 
Flow-FISH was used for the measurement of telomere length. The fluorescent PNA probes 
were hybridized to the telomere sequence and the signal was detected by Gallios flow 
cytometer. Kaluza software was used for the analysis. Fluorescent MESF-FITC beads were 
used and the QuickCal v2.3 data analysis program was used for the quantification of the 
fluorescent signal. The Telomere length was calculated according to this formula:  
Telomere length, kB = MESF 𝑥 nbase/ nchr𝑥 1000, where MESF is the fluorescent intensity given 
by QuickCal v.2.3, nbase is the number of bases per PNA probe and nchr is the number of 
chromosomes of HEL cells. 
4.13    LENTIVIRAL TRANSFECTION (PAPER II) 
KLF4 shRNA lentiviral particle was used for the lentiviral transfection. HEL cells were seeded 
at a density of 0.4 million/ml cultured with RPMI 1640 supplemented with 10% FBS, 1mg/ml 
L-glutamine and 1mg/ml penicillin/streptomycin. HEL cells were infected with the virus 
together with 5 μg/ml Polybrene. After 16 hours´ infection, the medium was changed followed 
by puromycin selection at a concentration of 1 μg/ml.  
4.14    CELL-BINDING ASSAY OF JEKO-1 CELLS (PAPER III) 
Human stromal cell line HS-5 and JeKo-1 cell line was cultured with RPMI supplemented with 
10% FBS, 100U/ml penicillin and 100 mg/mL streptomycin. JeKo-1 cells were labeled with 
Cell Tracer Carboxyfluorescein succinimidyl ester (CFSE, C34554 ThermoFisher),  and HS-5 
cells were labeled with Far-red (C34564 ThermoFisher) according to instructions of the 
manufacturer. SFSE labeled JeKo-1 was added to the HS-5 monolayer in the plate at 10:1 ratio. 
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After four hours of co-culture, adherent JeKo-1 cells were kept on the monolayer of HS-5 after 
trypsinization for 1 minute and PBS washing. For treatments, JeKo-1 cells after staining with 
CFSE were treated with compounds for one hour and then co-cultured with monolayer HS-5 
cells for four hours in the absence or presence of different concentrations of compounds and 
then cells were subjected to Flow cytometry analysis. 
4.15    ALOX5 KNOCKOUT WITH CRISPR/CAS9 (PAPER III) 
ALOX5 gene deletion in JeKo-1 cells was performed using CRISPR/Cas9 technique. Two 
different guide RNAs targeting ALOX-5 locus (AGATGGATGGAGTGGAACCC-TGG and 
CTATCAAACTGGATATCACG-GGG) (CRISPR evolution sgRNA EZ Kit, Synthego) and 
Cas9 protein (Alt-R® S.p. Cas9 Nuclease V3, IDT) were pre-complexed in ribonucleoproteins 
(RNPs). The RNPs were then introduced into the cells through electroporation with the Neon 
system (ThermoFisher Scientific) (1500V, 20 ms, 1pulse). The guides were designed against 
exon 4 of the ALOX-5 locus. The ALOX5 gene downstream ATG at exon 4 was mutated to 
avoid potential initiation.  
4.16    WHOLE TRANSCRIPT EXPRESSION ANALYSIS (PAPER II) 
To analyze the mechanism of CD34 cell accumulation after JAK2 inhibition, HEL cells treated 
with LY2784544 and/or GRN163L were analyzed with whole transcript expression analysis. 
Microarray assay was performed with Affymetrix whole-transcript expression analysis and the 
WT assay gene ST1.1 (Affymetrix, Santa Clara, CA, USA) according to the manufacture´s 
protocol and the Bioinformatic and Expression Analysis Core Facility (BEA), Karolinska 
Institutet.  
4.17    STATISTICAL ANALYSES 
IBM SPSS Statistics 24 software was used for the statistical analysis. One-way ANOVA test 
was used to compare the migration difference of different cell lines, and student t-test was used 
for JeKo-1 cell adherence assay, the results of TRAP, mRNA expression, colony formation 





5    RESULTS 
5.1    PAPER I  DNA METHYLATION DIFFERENCES IN HL TRIPLETS 
Four cell subtypes were examined in our study: CD34+ cells, Naïve B-cells, marginal zone-
like B-cells, and switched memory B-cells. Our results showed that four cell subpopulations 
were different from each other regarding the methylation status, as shown in Figure 5A. When 
we compared the HL triplets´ methylation status with the HL free triplet in the CD34+ cells 
and B cell subpopulations, shared methylation differences in naïve B-cells and marginal zone-
like B-cells were identified (Figure 5B). However, in CD34+ cells and switched memory B-
cells, no common methylation difference was detected. In the naïve B-cells and marginal zone-
like B-cells, all the methylation displayed the hyper-methylated status when compared with the 
HL free triplet.  
 
Figure 5. A. Unsupervised hierarchical clustering of methylation levels from the 10 000 most 
variable probes across all samples derived from the triplets. B. Overlaps of different 
methylated regions when each triplet is compared to the others in pairwise comparisons.  
Of all the regions screened in these four cell subtypes, we found that one region on chromosome 
18 differed in methylation in the naïve B-cells, where the gene CDH19 was located. In marginal 
zone-like B-cells, we detected 21 shared genomic regions on 10 different chromosomes. The 




Table 2. Genes with shared methylation differences in HL affected triplets compared with HL 
free triplet.
 
5.2    PAPER II 
5.2.1    The viability of HEL cells decreases after JAK2 inhibition and telomerase 
inhibition.  
The treatment of the specific JAK2 inhibitor LY2784544 at a concentration of 0.5 μM led to 
the decreased cell number, as well as cell viability when compared with the control group in 
erythroleukemia cell line HEL. However, the viability of HEL cells started to increase after 
several weeks of LY2784544 treatment and finally restored to the same level as control group 
in week 9. In cells treated with telomerase inhibitor GRN163L, no viability recovery was 
observed. When HEL cells were inhibited with both 0.5 μM LY2784544 and 20 μM GRN163L, 
no viability and apoptosis recovery was seen with the time after several weeks of treatment 






Figure 6. The viability of HEL cells after treated with LY2784544 and GRN163L, from week 1 
to week 9. 
5.2.2    CD34+ HEL cells accumulate after JAK2 inhibition.  
In LY2784544-treated group, the fraction of CD34+ HEL cells increased from 10% to about 
85% in week 9 (Figure 7A and 7C). However, in the control group, the CD34+ cells decreased 
over time. Combination treatment of LY2784544 and GRN163L did not induce the 
accumulation of the CD34+ cells compared with the control group and GRN163L treated group 
as shown in Figure 7B. After separation of the CD34+ and CD34- HEL cells, the viability and 
apoptotic cells were less in CD34- cells when compared with the CD34+cells after JAK2 
inhibition. More interestingly, in CD34- HEL cells, the percentage of CD34+ HEL cells 
increased after LY2784544 incubation with time. Colony assay results also showed that cells 




Figure 7. A. Fraction of CD34+ cells after LY2784544 treatment. B. Fraction of CD34+ cells 
after GRN163L and the combination treatment. C. Histograms of CD34-APC in HEL cells 
after LY2784544 treatment. D. Number of colonies after LY2784544 and GRN163L treatment. 
5.2.3    Silencing KLF4 expression reduces the LY2784544-mediated accumulation of 
CD34+ cells 
We performed the whole-transcript analysis of HEL cells pre-treated with JAK2 inhibitors, the 
gene KLF4 was selected for further analysis. It belongs to SP1-like family and was reported to 
regulate the stem cells in many features such as proliferation, apoptosis, etc. We found KLF4 
was upregulated, as confirmed by WB (Figure 8A). The inhibition of KLF4 was also identified 
after the combination treatment of JAK2 inhibitor LY2784544 and telomerase inhibitor 
GRN163L compared with the LY2784544 treatment alone. The lentiviral transfection was set 
up to knock down the expression of KLF4 through shKLF4 (Figure 8B and 8C). The 
accumulation of CD34+ cells mediated by LY2784544 treatment was attenuated after KLF4 









Figure 8. A. KLF4 protein expression after LY42784544 treatment. B. KLF4 protein 
expression after knocking down with ShKLF4. C. mRNA expression after KLF4 knock down. 
D. Histogram of CD34-APC in HEL cells after two weeks of LY2784544 incubation. 
5.2.4    JAK2 inhibition leads to the down-regulation of TERT and telomerase activity, 
but elongates telomere length. 
The decreased telomerase activity and TERT expression was detected after JAK2 inhibition 
compared with the control group. However, the telomere length was found to increase after 
LY2784544 incubation in week 7 and 9 (Figure 9A-B). This phenomenon was seen both in 
CD34+ and CD34- HEL cells, but telomere lengthening was more obvious in CD34+ cells. 
The longer the incubation time was, the more significant longer telomere length was, which 
was more significant in week 8 than week 4. The decreased telomerase activity was seen also 






Figure 9. A. Telomerase activity of HEL cells after LY2784544 treatment. B. Telomere length 
of HEL cells after LY2784544 treatment. C. Telomerase activity of CD34- and CD34+ HEL 
cells after LY2784544 treatment. D. Telomere length of CD34- and CD34+ HEL cells after 
LY2784544 treatment. 
5.3    PAPER III 
5.3.1    5-LOX/FLAP inhibitors inhibit the migration of JeKo-1 cells 
In human bodies, the spread of MCL cells in the vessels could result in many severe disease-
related symptoms. MCL cells contain a large amount of 5-LOX and mediate the production of 
the chemotactic LTB4. It was therefore of interest to determine whether the inhibition of 5-
LOX has an effect on the migration of these cells. We performed experiments to analyze 
whether 5-LOX and FLAP inhibitors influence the migration of MCL cells upon stimulation 
with the potent chemoattractant CXCL12. In our study, transwell assays were used for 
determination of the migration ability. As shown in Figure 11B, the MCL-derived JeKo-1 cells 
contain high large amounts of 5-LOX protein (91). The number of migrated JeKo-1 cells 
increased towards CXCL12 compared with JeKo-1 cells exposed to only SFM (Figure 10A). 
The migration of JeKo-1 cells towards medium which contains 20% FBS is also shown in 
Figure 10A. Inhibition of LT synthesis by the FLAP inhibitor GSK 2190915 (GSKi) or the 5-
LOX inhibitor zileuton results in the dose-dependent decreased migration of the cells upon 
stimulation with CXCL12. The migration of cells towards CXCL12 decreased significantly at 
the concentration of 0.5 μM of the inhibitors. To further determine whether the effect of the 
inhibitors was mediated by 5-LOX protein, we examined the effect of the inhibitors in 5-LOX 
negative cells. The T-cell line Jurkat expresses 5-LOX but not FLAP (92). As shown in Figure 
10B, LT biosynthesis inhibitors did not inhibit migration of these cells. Similar results were 
obtained with the T-cell line Molt-3 which does not express 5-LOX (92) (data not shown). 
Since LTB4 is a strong chemoattractant for neutrophils and T cells (93), we investigated 
whether LTB4 was a chemoattractant for JeKo-1 cells. However, LTB4 did not stimulate the 





Figure 10.  Effect of GSK 2190915 (GSKi) and Zileuton on the migration of JeKo-1 cells (A) 
Jurkat cells (B). 
5.3.2    Knocking out ALOX5 gene through CRISPR/Cas9 decreases the migration of 
JeKo-1 cells. 
By using the gene knockout technique CRISPR/Cas9, we established a stable ALOX5 gene 
negative JeKo-1 cell line (5-LOX KO) to further probe whether 5-LOX has an important role 
in migration of these cells. The absence of 5-LOX protein expression of ALOX5 in JeKo-1 
cells is shown in Figure 11B. The spontaneous migration in serum-free medium (SFM) or upon 
stimulation with CXCL12, were significantly decreased in 5-LOX negative JeKo-1 cells in 
comparison with wild type JeKo-1 cells (Figure 11A). 
         
                                                                     
Figure 11. A. Migration of wild type JeKo-1 cells and ALOX5 KO cells after stimulation with 





5.3.3    5-LOX/FLAP inhibitors decrease the adhesion of JeKo-1 cells to stromal cells 
The adhesion ability of malignant B-cells to stromal cells in bone marrow, lymph nodes and 
other tissues is also an important pathophysiological event in the spreading of malignant B-
cells to other tissues or organs in the body. JeKo-1 cells could adhere to stromal cells (HS-5) 
(94). Since LTB4 mediates the stimulation of neutrophils adherent to the vessel wall (93), we 
explored the effect of 5-LOX and FLAP inhibitors on the adherence of JeKo-1 cells to the 
human stromal cell line HS-5 (Figure 12). JeKo-1 cells were firstly incubated with these 
inhibitors for 1 hour and then cells were cultured together with stromal cells for another 4 hours. 
FLAP inhibitors GSK2190915 (GSKi) and MK886, and the 5-LOX inhibitor zileuton could 
significantly decrease the number of adherent JeKo-1 cells, starting from the concentration of 
0.2μM. These compounds were as potent as ibrutinib regarding the inhibition of adherence of 
the cells. Our study showed a dose-dependent inhibition effect when cells were treated with 
MK886 and zileuton, while the maximum effect was shown already observed at the 
concentration of 0.2 μM for GSKi and ibrutinib. Cell viability was higher than 97% in all 
experiments (data not shown). 
 




5.3.4    Effect of 5-LOX/FLAP inhibitors on the cell surface expression of CXCR4 in 
JeKo-1 cells 
The chemotactic agent CXCL12 mediates mainly its effect through binding to the CXCR4 
receptor on the target cell. We investigated whether 5-LOX/FLAP inhibitors influenced the 
expression of CXCR4 in JeKo-1 cells. However, neither 5-LOX or FLAP inhibitors nor 
ibrutinib showed any effect on the expression of CXCR4 in JeKo-1 cells (Figure 13) 
 
Figure 13. Relative surface expression of CXCR4 in JeKo-1 cells after treatment with different 
compounds. 
 
Figure 14. Theoretical model of the effects of 5-LOX/FLAP inhibitors on the migration and 





6    DISCUSSION AND CONCLUSIONS 
6.1    DNA METHYLATION DIFFERENCES IN HL MONOZYGOTIC TRIPLETS 
In this paper (I), we determined the methylation differences of PBMCs from three monozygotic 
triplets, of which two were diagnosed with HL, the other one is HL-free. The methylation 
analysis was performed in four subtypes of cells, CD34+ stem cells and three B cell-
subpopulations (naïve-B cells, marginal zone-like B-cells, switched memory B-cells). We 
identified the shared DNA methylation differences in naïve B-cells and marginal zone-like B-
cells. Some of the genes in the shared methylated regions were related to the development of 
cancer or hematopoiesis in humans and animals. For example, ISM1 was reported to be 
expressed in the lymphocytes, bone marrow, or embryonic blood islands. In zebrafish, it was 
related to hematopoiesis, especially in the production of hematopoietic stem and progenitor 
cells (95). KLH22 could promote the tumor-genesis through the regulation of mTORC1, and 
the depletion of KLH22 in breast cancer cells inhibits the tumor development in mice models 
(96). Small nucleolar RNA host gene 18 (SNHG18), recently reported to play as a tumor 
suppressor in hepatocellular cancer, could also be potentially used as the diagnostic biomarker 
for hepatocellular carcinoma (97). The lncRNA SNHG18 also regulates the cell motility in 
Glioma (98). MRAS could function as a key signal transducer, and regulate the tumor growth 
through activation of many important signal pathways such as MAPK and ERK pathways (99). 
KDR was known to be related to angiogenesis, vascular development and embryonic 
hematopoiesis. The mutation (p.A 1065T) of KDR gene has the potential to promote the tumor 
proliferation (100). 
The mechanism causing the methylation difference between HL affected triplets and the HL 
free triplet is unknown. The difference might be due to the inter-individual variation, 
environmental factors, living habits between them or some stochastic events. Since both of the 
HL-triplets got chemotherapy treatment when they were diagnosed at the age of 40 and 63, 
respectively, we can not exclude the potential effect of chemotherapy on the methylation 
differences in these triplets. Some studies demonstrated that chemotherapy could affect the 
epigenetic pattern. In one study, the 4-month chemotherapy treatment was found to change the 
DNA-methylation in breast cancer patients (101). In that study, CpG islands in or close to the 
genes SDK1, SUF2, VMP1 and CORO1B were found to be changed after the chemotherapy. 
After comparison with the genes we screened, none of the above genes were found to be 
hypermethylated in our study. Interestingly, we found that the SUMF2 paralog SUMF1 was 
altered in marginal zone-like B-cells from both HL triplets. It has been reported that SUMF2 
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inhibits the suphatase-enhancing activity of SUMF1 (102). We will investigate if this is the 
case in the HL triplets. 
The DNA hyper-methylation we observed in this case probably could lead to the low 
expression of these genes. Some studies suggest that the inherited-associated somatic mutations 
might show a low effect on clonal hematopoiesis, which indicates the higher impact of DNA 
methylation in clonal hematopoiesis (103, 104). It would be of great interest to investigate the 
epigenetic pattern, especially the DNA methylation in the future in HL and other hematological 
diseases.  
In summary, we here report the DNA methylation differences in three unique monozygotic HL 
triplets. Some CpG islands of the DNA isolated from marginal zone-like B-cells and naïve-B 
cells were found to be hypermethylated in HL triplets compared with the HL free triplet, which 
may have a general implication in the pathogenesis of HL. 
 
6.2    MUTATION OF JAK2V617F-BEARING LEUKEMIA CELLS THROUGH JAK2 
INHIBITION ACCUMULATES CD34+ LEUKEMIC STEM CELLS THAT ARE 
ABOLISHED BY THE TELOMERASE INHIBITOR GRN163L 
JAK2V617F mutation is important in driving MPN development. JAK2 inhibitors are now 
established for MPN treatment. JAK2 inhibition exhibited certain positive effects but is unable 
to eradicate the disease clone (105). Our findings suggest that the apoptosis and proliferation 
of HEL cells that carry JAK2V617F could be affected by the JAK2 inhibitor LY2784544 during 
the first week of treatment, but these effects could be diminished with longer inhibitor 
treatment. CD34+ cell accumulation may be the reason causing this phenomenon. We found 
that the stem cell factor KLF4 could be upregulated by the LY2784544 treatment. 
KLF4 was reported to induce the production of iPSCs by combining with other three 
transcriptional factors (Oct3/4, Sox2, c-Myc) (106). However, how KLF4 is acting in 
hematopoiesis, is not fully clarified. It may be related to the de-differentiation indicating the 
role of KLF4 in the maintenance of tissue-specific stem cells. We found that the silence of 
KLF4 attenuated the LY2784544 mediated CD34+ cells´ enrichment, but it was not totally 
blocked. Similar to our study, KLF4 was found to be down-regulated in CD34+ cells from PV 
patients, and KLF4 was upregulated followed by JAK2V617F inhibition (107). Our findings and 
other reports suggested KLF4 was a potential target in the treatment of MPNs. JAK2/STAT 





STAT3/STAT5 at the promoter region in human hematological malignancies (41). This 
suggests a close relation between JAK2 and TERT in the development of malignancies. In our 
studies, we found that LY2784544 decreased the expression of TERT as well as telomerase 
activity. But the telomere length was elongated in HEL cells during LY2784544 incubation. It 
would be of great interest to further determine how JAK2 inhibitors cause the elongation of 
telomere in MPN cells and how the treatment failure occurs. 
We found that telomerase inhibitor GRN163L decreased the accumulation of CD34+ HEL 
cells mediated by LY2784544 treatment. Also, the elongation of telomere length caused by 
LY2784544 could be reversed by GRN163L treatment. The accumulation of CD34+ cells was 
also found to be present in CD34- cells, suggesting the treatment of LY2784544 might convert 
cells to a more immature status. However, the remaining CD34+ cells after CD34+ cell 
isolation that were resistant to the LY2784544 treatment may also result in the accumulation 
of CD34+ cells in CD34- cells. If so, our study showed that the CD34+ HEL cells could tolerate 
LY2784544 more than CD34- cells. 
In summary, we here demonstrated that JAK2 inhibitor LY2784544 caused the enrichment of 
CD34+ cells through induction of KLF4 expression in the JAK2V617F HEL cell line. This 
phenomenon was attenuated by KLF4 silencing. Targeting both KLF4 and JAK2V617F may 
have better efficacy for the treatment of MPNs. The telomerase inhibitor GRN163L could 
reverse the accumulation of CD34+ cells after LY2784544 treatment, which suggests the 
potential therapeutic effect of combination of JAK2 inhibitors and telomerase inhibitors in the 
treatment of MPNs. 
 
6.3    INTRINSIC 5-LIPOXYGENASE ACTIVITY REGULATES THE MIGRATION 
AND ADHESION OF MANTLE B-CELL LYMPHOMA CELLS 
 The migration and adhesion of MCL cells is a very important mechanism for the spread of 
these cells in the body. Thus, the inhibition of cellular migration and adhesion will reduce 
dissemination to secondary lymphatic tissues via systemic circulation. Here, we found that the 
inhibition of the 5-LOX pathway through 5-LOX or FLAP inhibitors could result in the 
decrease of the migration and adherence ability of the MCL cell line JeKo-1 in vitro, and this 
inhibitory effect was as potent as BTK inhibitor Ibrutinib. It was reported that the main 
mechanism of ibrutinib affecting tumors was to change the redistribution status of the 
malignant cells rather than cytotoxicity (108). 
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We also found that the effect of 5-LOX/FLAP inhibitors on cell migration was dependent on 
the 5-LOX expression since these inhibitors did not inhibit the migration of the T cell lines 
Jurkat and Molt-3, which are 5-LOX negative (92). Furthermore, CRISPR/Cas9 mediated 
deletion of the ALOX5 gene in JeKo-1 cells caused the decrease in the migration of JeKo-1 
cells. 
It has been known that most of the B lymphocytes contain high amounts of 5-LOX protein, but 
germinal center B cells express very low or no amounts of 5-LOX protein (91, 109, 110). Likely, 
the main role of the 5-LOX pathway in B cells is to guide the cells to secondary lymphoid 
organs where the cells are either transformed into plasma cells or undergo apoptosis. Cells 
trafficking to secondary lymphatic tissues is a way to escape from the immune system and 
thereby reduce cell apoptosis in malignant cells (111, 112). Secondary lymphatic stromal cells 
are known to generate chemoattract CXCL12 and some other chemokines, which guide 
malignant B cells to move towards lymph node compartments (113). The chemokine CXCL12 
induces cell chemotaxis and adhesion. CXCL12 is playing a role through binding to its receptor 
CXCR4. The crosstalk between malignant B-cells and the stromal micro-environment is an 
essential mechanism in the spread of the MCL cells (114). Our results showed that the 
adherence ability of JeKo-1 cells to stromal cells was inhibited by 5-LOX/FLAP inhibitors. 
Interestingly, our study showed that LTB4 did not induce the migration of B cells, but it is well-
known that LTB4 is a potent chemotactic agent for neutrophils and T cells (76). LTB4 hasn´t 
been reported to be released through the activation with calcium ionophore or under 
physiological conditions in normal or malignant B lymphocytes (115). Moreover, LTB4 was 
not chemotactic for MCL cells. These results suggest an additional intracellular signaling role 
for 5-LOX derived mediators in B lymphocytes that is different from their well-known function 
as metabolites promptly released from the cells upon activation. This indicates that 5-LOX 
protein in B lymphocytes may play an intrinsic role in cells. Figure 14 is a drawing showing a 
proposed effect of 5-LOX/FLAP inhibitors. Previous studies have shown an intrinsic function 
of the 5-LOX pathway in acute myeloid leukemia cells (116) and neutrophils (117, 118). 
Moreover, the intrinsic neutrophil 5-LOX activity regulates the adherence and chemotaxis of 
neutrophils in vitro (117). 
In fact, there are also several other studies demonstrating that 5-LOX has an intrinsic function. 
It has been shown that 5-LOX is related to the pathophysiological function through the 
interplay with various nuclear proteins such as dicer, p53, and the Wnt/beta-catenin signaling 
pathway (119).  The modulation of microRNA by 5-LOX is another important non-canonical 





located in the nucleus of tissue B lymphocytes (115) and the production of LTs could also be 
found in the nucleus (121, 122). Thus, we could not rule out the possibility that certain 
biological actions of 5-LOX might be due to its ability to generate the reactive oxygen species 
or LTs in the cell nucleus.  
The phosphorylation of 5-LOX through different kinds of kinases has also been shown to 
activate the enzyme or be related to its transportation between cytoplasm and cell nucleus (123).  
A partial of 5-LOX is very likely to be phosphorylated continuously at Ser 523 in B-cells (124).  
It remains to be further explored if this phosphorylation of 5-LOX is correlated with the change 
from an extrinsic role to its intrinsic function of the enzyme in B lymphocytes. Taken together, 
it is likely that the intrinsic function of 5-LOX in B cells play an important biological role in 
these cells. 
By now, two different FLAP inhibitors have entered clinical phase I and II studies for several 
diseases. GSK 2190915 has been used as the treatment strategy of asthma in a clinical phase II 
study (65). Another kind of FLAP inhibitor, AZD5718, has tentatively been shown to be useful 
for the treatment of coronary artery disease. So far, it has been tested in a phase I study. The 
LTB4 levels in plasma decreased over 90 % and the drug was well-tolerated (125).   
In summary, the present study demonstrates that 5-LOX/FLAP inhibitors inhibit migration and 
adherence of MCL cells, indicating that these compounds might be useful for the treatment of 












7    POINTS OF PERSPECTIVE
In paper I, we determined the DNA methylation status of the PBMCs from CD34+ cells and 
three  B  cell  subpopulations  from  monozygotic  triplets  two  of  whom   were  diagnosed with 
HL, while  the  other  remains  HL  free. We  found  the  genes  in  several  regions  are  hyper- 
methylated in Naïve-B cells and Marginal zone-like B-cells in both HL triplets compared 
with  the  HL  free  triplet.  Some  of  these  genes  are  related  to  cancer  development  or 
hematopoiesis. It helps us to understand the pathogenesis of HL. Further study, such as other 
epigenetic  changes  that  happened  in  other  twin  studies  in  HL  and  other  hematological 
diseases, could further help us to understand the development of hematopoiesis, and the role 
of epigenetics in the pathogenesis of HL.
In paper II, we found that JAK2 inhibitor LY2784544 caused the accumulation of CD34+ 
cells in HEL cell line which carries JAK2V617F mutation, coupled with KLF4 upregulation. 
The combination of KLF4 and JAK2 inhibitions or JAK2 plus telomerase inhibitors may be 
potentially used as a therapeutic strategy for MPNs. In future studies, how JAK2 inhibition 
causes the KLF4 upregulation is needed to be further clarified.
In paper III, we demonstrated that 5-LOX/FLAP inhibitors inhibit migration and adherence 
of MCL cells, indicating that these compounds might be useful for the treatment and MCL. 
We will continue with the study of the mechanism of how 5-LOX pathway influences the 
migration  of  B-cells,  and  importantly,  other  clinical  trials  also  need  to  show  which  MCL 
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